会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • Use of microproteins as tryptase
    • 使用微蛋白作为类胰蛋白酶
    • US20090130692A1
    • 2009-05-21
    • US11663435
    • 2005-09-19
    • Harald KolmarChristian SommerhoffAlexander Wentzel
    • Harald KolmarChristian SommerhoffAlexander Wentzel
    • G01N33/567C07K14/00C07H21/00C12N9/24C07H21/04C12N5/10C12Q1/34A61K38/47C12P21/02C12N15/63A61K35/12A61K31/7088A61K38/16
    • A61K38/56C07K14/47C07K2319/00C30B7/00C30B29/58
    • Disclosed are uses of microproteins preferably microproteins forming a cystine knot (i.e. belonging to the family of inhibitor cystine knot (ICK) polypeptides) or polynucleotides encoding said microproteins for the preparation of a pharmaceutical composition for treating or preventing a disease that can be treated or prevented by inhibiting the activity of tryptase as well as corresponding methods of treatment. Also disclosed are uses of the microproteins for inhibiting tryptase activity, for purifying tryptase, as a carrier molecule for tryptase and for deleting or quantifying tryptase in a sample, including corresponding diagnostic applications. Furthermore disclosed are fusion proteins comprising an inactive barnase as well as fusion proteins comprising barnase and a microprotein. Also encompassed are nucleic acid molecules encoding such a fusion protein, as well as corresponding vectors, host cells, preparation methods and uses of the fusion protein. Moreover, the present application discloses a crystal of a microprotein fused with barnase, preferably inactive barnase. The disclosure also refers to corresponding preparation methods for the crystal, structure analysis methods using the crystal data storage media comprising the structure data obtained, as well as to in silico methods using the structure data for characterizing the binding of microproteins to target molecules. Furthermore, disclosed are pharmaceutical compositions comprising the crystal and corresponding medical uses.
    • 公开了微型蛋白质的使用,优选微型蛋白质形成胱氨酸结(即属于抑制剂胱氨酸结(ICK)多肽家族)或编码所述微蛋白的多核苷酸用于制备用于治疗或预防可被治疗或预防的疾病的药物组合物 通过抑制类胰蛋白酶的活性以及相应的治疗方法。 还公开了微蛋白用于抑制类胰蛋白酶活性,纯化类胰蛋白酶的作用,作为类胰蛋白酶的载体分子以及删除或定量样品中的类胰蛋白酶的用途,包括相应的诊断应用。 此外,还公开了包含非活性芽孢杆菌RNA酶的融合蛋白以及包含芽孢杆菌RNA酶和微蛋白的融合蛋白。 还包括编码这种融合蛋白的核酸分子,以及相应的载体,宿主细胞,制备方法和融合蛋白的用途。 此外,本申请公开了一种与芽孢杆菌酶融合的微蛋白的晶体,优选不活泼的芽孢杆菌RNA酶。 本公开还涉及晶体的相应制备方法,使用包含所获得的结构数据的晶体数据存储介质的结构分析方法,以及使用结构数据表征微结构蛋白与靶分子的结合的计算机方法。 此外,公开了包含晶体和相应医疗用途的药物组合物。
    • 4. 发明授权
    • Method for exposing peptides and polypeptides on the cell surface of bacteria
    • 在细菌细胞表面上暴露肽和多肽的方法
    • US07186524B2
    • 2007-03-06
    • US10415165
    • 2001-10-25
    • Harald KolmarAndreas ChristmannAlexander Wentzel
    • Harald KolmarAndreas ChristmannAlexander Wentzel
    • C12P21/06C12N1/20C12N15/00
    • C12N15/70C07K14/245C07K2319/00C12N11/16
    • The inventive method allows peptides or polypeptides to be exposed on the surface of gram-negative host bacteria using specific intimin-based anchor modules. Intimins with shortened carboxy terminals have been found to be particularly suitable anchor modules for passenger domains in the exterior E. coli cell membrane. According to the method, host bacteria are transformed using vectors, on which are located a fused nucleic acid sequence consisting of a sequence segment which codes for an intimin with a shortened carboxy terminal and a nucleic acid sequence segment which codes for the passenger peptide that is to be exposed. The invention permits a particularly large number of passenger domains to be exposed on the cell surface of the bacteria, without adversely affecting the viability of the bacteria.
    • 本发明的方法允许使用特定的基于Intimin的锚模块将肽或多肽暴露在革兰氏阴性宿主细菌的表面上。 已经发现具有缩短的羧基末端的内皮素特别适用于外部大肠杆菌细胞膜中的载体结构域的锚模块。 根据该方法,使用载体转化宿主细菌,其中位于由编码具有缩短的羧基末端的肠溶蛋白的序列区段和由序列片段编码的载体肽所构成的核酸序列片段的融合核酸序列 被暴露。 本发明允许特别大量的乘客区域暴露在细菌的细胞表面上,而不会不利地影响细菌的存活力。
    • 6. 发明授权
    • Use of microproteins as tryptase inhibitors
    • 使用微蛋白作为类胰蛋白酶抑制剂
    • US08278262B2
    • 2012-10-02
    • US11663435
    • 2005-09-19
    • Harald KolmarChristian SommerhoffAlexander Wentzel
    • Harald KolmarChristian SommerhoffAlexander Wentzel
    • A61K38/00G01N33/567
    • A61K38/56C07K14/47C07K2319/00C30B7/00C30B29/58
    • Disclosed are uses of microproteins preferably microproteins forming a cystine knot (i.e. belonging to the family of inhibitor cystine knot (ICK) polypeptides) or polynucleotides encoding said microproteins for the preparation of a pharmaceutical composition for treating or preventing a disease that can be treated or prevented by inhibiting the activity of tryptase as well as corresponding methods of treatment. Also disclosed are uses of the microproteins for inhibiting tryptase activity, for purifying tryptase, as a carrier molecule for tryptase and for deleting or quantifying tryptase in a sample, including corresponding diagnostic applications. Furthermore disclosed are fusion proteins comprising an inactive barnase as well as fusion proteins comprising barnase and a microprotein. Also encompassed are nucleic acid molecules encoding such a fusion protein, as well as corresponding vectors, host cells, preparation methods and uses of the fusion protein. Moreover, the present application discloses a crystal of a microprotein fused with barnase, preferably inactive barnase. The disclosure also refers to corresponding preparation methods for the crystal, structure analysis methods using the crystal data storage media comprising the structure data obtained, as well as to in silico methods using the structure data for characterizing the binding of microproteins to target molecules. Furthermore, disclosed are pharmaceutical compositions comprising the crystal and corresponding medical uses.
    • 公开了微型蛋白质的使用,优选微型蛋白质形成胱氨酸结(即属于抑制剂胱氨酸结(ICK)多肽家族)或编码所述微蛋白的多核苷酸用于制备用于治疗或预防可被治疗或预防的疾病的药物组合物 通过抑制类胰蛋白酶的活性以及相应的治疗方法。 还公开了微蛋白用于抑制类胰蛋白酶活性,纯化类胰蛋白酶的作用,作为类胰蛋白酶的载体分子以及删除或定量样品中的类胰蛋白酶的用途,包括相应的诊断应用。 此外,还公开了包含非活性芽孢杆菌RNA酶的融合蛋白以及包含芽孢杆菌RNA酶和微蛋白的融合蛋白。 还包括编码这种融合蛋白的核酸分子,以及相应的载体,宿主细胞,制备方法和融合蛋白的用途。 此外,本申请公开了一种与芽孢杆菌酶融合的微蛋白的晶体,优选不活泼的芽孢杆菌RNA酶。 本公开还涉及晶体的相应制备方法,使用包含所获得的结构数据的晶体数据存储介质的结构分析方法,以及使用结构数据表征微结构蛋白与靶分子的结合的计算机方法。 此外,公开了包含晶体和相应医疗用途的药物组合物。